Compare MPAA & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPAA | ACIU |
|---|---|---|
| Founded | 1968 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.6M | 213.3M |
| IPO Year | 1994 | 2016 |
| Metric | MPAA | ACIU |
|---|---|---|
| Price | $12.94 | $3.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $20.00 | $10.00 |
| AVG Volume (30 Days) | 103.9K | ★ 416.8K |
| Earning Date | 02-09-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $789,115,000.00 | $5,482,957.00 |
| Revenue This Year | $9.76 | N/A |
| Revenue Next Year | $5.81 | $644.42 |
| P/E Ratio | $107.08 | ★ N/A |
| Revenue Growth | ★ 6.72 | N/A |
| 52 Week Low | $5.38 | $1.43 |
| 52 Week High | $18.12 | $4.00 |
| Indicator | MPAA | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 49.86 | 59.56 |
| Support Level | $12.56 | $3.24 |
| Resistance Level | $13.70 | $3.80 |
| Average True Range (ATR) | 0.52 | 0.27 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 54.85 | 67.42 |
Motorcar Parts of America Inc is a supplier of automotive aftermarket non-discretionary replacement parts and test solutions and diagnostic equipment. It operate in the non-discretionary automotive aftermarket for replacement hard part in North America and includes products such as light-duty rotating electrical products, wheel hub products, brake-related products, and turbochargers. In addition, it sell test solutions and diagnostic equipment. The company operates in three segments Hard Parts, Test Solutions and Diagnostic Equipment, and Heavy Duty. Key revenue is generated from Hard Parts, which includes (i) light duty rotating electric products such as alternators and starters, (ii) wheel hub products, (iii) brake-related products, including brake calipers, brake boosters, brake rotors.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.